Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

Full DD Report for REGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: REGN)

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
TARRYTOWN, N.Y. , Sept. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of EYLEA ® (aflibercept) Injection f...
Source: PR Newswire
Date: September, 13 2018 07:00
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
BRIDGEWATER, N.J. and TARRYTOWN, N.Y. , Sept. 12, 2018 FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA...
Source: PR Newswire
Date: September, 12 2018 08:00
FDA to review sBLA for Praluent Injection as potential treatment to reduce MACE
Regeneron Pharmaceuticals (NASDAQ: REGN ) and Sanofi (NYSE: SNY ) announces that the FDA has accepted a supplemental Biologics License Application (sBLA) for Praluent (alirocumab) Injection, a PCSK9 inhibitor. More news on: Regeneron Pharmaceuticals, Inc., Sanofi, Healthcare stocks ...
Source: SeekingAlpha
Date: September, 12 2018 06:47
FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
TARRYTOWN, N.Y. and PARIS , Sept. 12, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Praluent ® (alirocumab) Injecti...
Source: PR Newswire
Date: September, 12 2018 00:59

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-14390.28397.71398.565389.25538,791
2017-07-27515.77508.41517.44503.98958,059
2017-07-26513.77515.63518.57510.00369,478
2017-07-25523.97513.45526.12510.74596,286
2017-07-24516.94521.22521.77510.70474,355

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0797,106159,45160.9002Short
2018-12-06100,163166,73760.0724Short
2018-12-04104,783190,30655.0603Short
2018-12-03138,501295,09446.9345Short
2018-11-3063,953129,83549.2571Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on REGN.


About Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

Logo for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

Not available

 

Contact Information

 

 

Current Management

  • Leonard S. Schleifer / President, CEO
  • Murray A. Goldberg / CFO

Current Share Structure

  • Market Cap: $31,976,716,381 - 05/18/2018
  • Issue and Outstanding: 105,949,824 - 04/12/2018

 


Recent Filings from (NASDAQ: REGN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 02 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: July, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: REGN)

Daily Technical Chart for (NASDAQ: REGN)


Stay tuned for daily updates and more on (NASDAQ: REGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: REGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in REGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of REGN and does not buy, sell, or trade any shares of REGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/